Sitaxsentan: A novel endothelin - A receptor antagonist for pulmonary arterial hypertension

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 6, 2005, Pages 985-991

  Widlitz, Allison C ^a   Barst, Robyn J ^a   Horn, Evelyn M ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Endothelin; Endothelin receptor antagonist; Pulmonary arterial hypertension; Sitaxsentan

Indexed keywords

BOSENTAN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROTHROMBIN; SILDENAFIL; SITAXSENTAN; WARFARIN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EPISTAXIS; EXERCISE; FLUSHING; HEADACHE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HUMAN; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; NAUSEA; NONHUMAN; NOSE CONGESTION; PERIPHERAL EDEMA; PHYSICAL CAPACITY; PROTEIN FUNCTION; PROTHROMBIN TIME; PULMONARY HYPERTENSION; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASOCONSTRICTION; VOMITING; WALKING;

CLINICAL TRIALS; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; RECEPTORS, ENDOTHELIN; THIOPHENES;

EID: 28644439786     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.3.6.985     Document Type: Review

References (38)

1. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 107, 216-223 (1987).
2. Rich S. Executive Summary from the World Symposium on Primary Pulmonary Hypertension, Geneva. WHO Press, World Health Organization, Geneva, Switzerland (1998).
3. Rubin, LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126, S7-S10 (2004).
4. Rubin LJ. Primary pulmonary hypertension. N. Engl. J Med. 336, 111-117 (1997).
5. Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH 1) is caused by mutations in the bone morphogenetic protein-receptor II gene. 67, 737-744 (2000).
6. Speich R, Jenni R, Opravil M et al. Primary pulmonary hypertension in HIV infection. Chest 100, 1268-1271 (1991).
7. Humbert M, Nunes H, Sitbon O et al. Risk factors for pulmonary arterial hypertension. Clin. Chest Med. 22, 459-475 (2001).
8. Koh ET, Lee P, Gladman DD et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheumatol. 35, 989-993 (1996).
9. Stupi A, Steen VD, Owens GR et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 29, 515-524 (1986).
10. Ungerer RG, Tashkin DP, Furst D et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am. J. Med. 73, 65-74 (1983).
11. Sturfelt G, Eskilsson J, Nived O et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine 71, 216-223 (1992).
12. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. 327(2), 76-81 (1992).
13. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110(6), 660-665 (2004).
14. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334, 196-302 (1996).
15. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. 132, 425-434 (2000).
16. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med 165(6), 800-804 (2002).
17. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual-endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288), 1119-1123 (2001).
18. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002).
19. Barst RJ, Ivy D, Dingemanse J et al. Single- and multiple-dose pharmacokinetics of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 73, 372-382 (2003).
20. Galie N, Ghofrani H, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) (In Press).
21. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163), 411-415 (1988).
22. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102(19), 2434-2440 (2000).
23. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC. Function of the endothelin B receptor in cardiovascular physiology and pathophysiology. Pharmacol. Ther. 95(3), 221-238 (2002).
24. Jeffery TK, Wanstall JC. Pulmonary vascular remodelling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol. Ther. 91, 1-20 (2001).
25. Joannides R, Haefeli WE, Linder L et al. Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 91, 1314-1319 (1995).
26. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 61(2), 227-237 (2004).
27. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41, 851-876 (2001).
28. B receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin. Sci. 104(2), 143-151 (2003).
29. Wu C, Chan MF, Stavros F et al. Discovery of TBC11251, a potent, long acting, orally-active endothelin receptor-A selective antagonist. J. Med. Chem. 40(11), 1690-1697 (1997).
30. Givertz MM, Colucci WS, LeJemtel TH et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 101(25), 2922-2927 (2000).
31. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 121(6), 1860-1868 (2002).
32. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(4), 441-447 (2004).
33. Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41(12), 2119-2125 (2003).
34. McLaughlin VV, Hill N, Tapson VF et al. Sitaxsentan improves 6MW in patients with pulmonary arterial hypertension (PAH) related to connective-tissue diseases (CTD). Chest 126(4), S759 (2004)
35. Horn E, Langleben D, Frost A et al. Chronic sitaxsentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169(7), A210 (2004).
36. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a one year follow-up study. Chest. 126(4), 1377-1381 (2004).
37. Tilton RG, Munsch CL, Sherwood SJ et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally-active ET(A) receptor antagonist. Pulm. Pharmacol. Ther. 13(2) 87-97 (2001).
38. Dupius J. Endothelial receptor antagonists in pulmonary arterial hypertension. Lancet 358(9288), 1113-114 (2001).